PMID- 27160959
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20181202
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 28
IP  - 1
DP  - 2017 Feb
TI  - Benefit-risk tradeoff preferences for chronic hand eczema treatments.
PG  - 40-46
LID - 10.1080/09546634.2016.1177161 [doi]
AB  - Hand eczema affects approximately 16% of the US population. The long-term 
      prognosis is poor, and 5-7% experience severe chronic hand eczema (sCHE) that 
      interferes with daily activities. Treatments for CHE may be ineffective or 
      associated with adverse events (AEs) that may dissuade patients from pursuing or 
      continuing treatment. For quantification of patient experiences and benefit-risk 
      preferences for outcomes associated with CHE treatments, a web-based discrete 
      choice experiment survey was administered to patients in the United States with a 
      self-reported physician diagnosis of CHE and severe symptoms not resolved with 
      topical agents. Respondents answered a series of treatment choice questions, each 
      requiring evaluation of a pair of hypothetical profiles of medications for sCHE 
      defined by efficacy and risk of several AEs. Improvement in CHE clearing of 
      25-50% was rated from 1.5 to 3.1 times as important as eliminating a 5% risk of 
      permanent bone problems. The mean maximum acceptable risk of permanent vision 
      problems in exchange for an improvement in CHE clearing of 25-50% ranged from 
      3.4% to 4.8%. This study demonstrated that patients with CHE rated efficacy 
      improvements associated with treatment of sCHE as more important than eliminating 
      the risks of specific AEs.
FAU - Hauber, A Brett
AU  - Hauber AB
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Mohamed, Ateesha F
AU  - Mohamed AF
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Gonzalez, Juan Marcos
AU  - Gonzalez JM
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Otteson Fairchild, Angelyn
AU  - Otteson Fairchild A
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Zelt, Susan C
AU  - Zelt SC
AD  - b Steifel, a GSK Company , Research Triangle Park , NC , USA.
FAU - Graff, Ole
AU  - Graff O
AD  - b Steifel, a GSK Company , Research Triangle Park , NC , USA.
LA  - eng
PT  - Journal Article
DEP - 20160510
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Eczema/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - Patient preference
OT  - discrete choice experiment
OT  - maximum acceptable risk
OT  - treatment characteristics
EDAT- 2016/05/11 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/05/11 06:00
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PHST- 2016/05/11 06:00 [entrez]
AID - 10.1080/09546634.2016.1177161 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2017 Feb;28(1):40-46. doi: 10.1080/09546634.2016.1177161. 
      Epub 2016 May 10.